-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors
Original Research
(2011) Views (589) Full article downloads
Authors: Shaojin You, Lian Zuo, Wei Li
Published Date March 2010
Volume 2010:5 Pages 221 - 229
DOI: http://dx.doi.org/10.2147/IJN.S8488
Shaojin You, Lian Zuo, Wei Li
Experimental Cancer Therapeutic Laboratory and Histopathology Core, Atlanta Research and Educational Foundation (151F), Atlanta VA Medical Center, Decatur, GA, USA
Abstract: Sex hormonal milieus during the female fertility cycle modulate the tumor vascular permeability of breast cancer. It has been proposed that the liposomal formulated doxorubicin (ie, Doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular permeability, allows significantly increased drug retention in the breast tumor. In the current study, syngeneic murine 4T1 mammary tumors were established on the backs of female BALB/c mice and Doxil was administered at particular mouse estrous cycle stages. The results indicated that Doxil administration during certain times in the mouse estrous cycle was crucial for drug retention in 4T1 tumor tissues. Significantly higher drug concentrations were detected in the tumor tissues when Doxil was administered during the diestrus stage, as compared to when the drug injection was given at all other estrous stages. Our study also showed that the tumor-bearing mice exhibited nearly normal rhythmicity of the estrous cycle post drug injection, indicating the feasibility of continual injection of Doxil at the same estrous cycle stage. By using 4T1 cells cultured in vitro, we showed that progesterone (P4) significantly inhibited cell proliferation and the production of six tumor-derived cytokines, eg, sTNF-RI, CXCL-16, GM-CSF, MIP-1α, MIP-1γ, and Flt3-L. Some of these factors have been shown to be vascular modulators in diverse tissues. In this report, we demonstrated that the concentration of P4 in the plasma and/or estrous cycle stage of 4T1 tumor-bearing mice can be used to select the best time for administrating the liposomal anticancer drugs.
Keywords: progesterone, menstrual cycle, mouse mammary tumor, Doxil, breast cancer therapy
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
The effect of acetaminophen nanoparticles on liver toxicity in a rat model
Nanomedicine for the reduction of the thrombogenicity of stent coatings
Amino acid management of Parkinson’s disease: a case study
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases




